GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cellid Co 299660.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

1,758

-4.46%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cellid Co

Its shares trade on KOSDAQ under the ticker 299660.KQ. It has been listed since 20 February 2019. In the fiscal year to 31 December 2025, it reported revenue of ₩8.84bn and a net loss of ₩12.07bn. At that date it held total assets of ₩110.87bn and shareholders' equity of ₩74.21bn.

Cellid Co., Ltd. is engaged in developing immunotherapeutic vaccines. The company is headquartered in Seoul, Seoul. The company went IPO on 2019-02-20. The firm develops cancer therapeutic vaccine through development and clinical research of BVAC pipeline products using CeliVax original technology.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
20 Feb 2019
Employees
59

Leadership

Pay as last reported

  • Mr. Chang Yul KangChief Executive Officer, Director
  • Mr. Se Hyeon JungManaging Director, Director
  • Mr. Chang Min OkAssistant Managing Director
  • Mr. Myeong Hwan ParkInternal Auditor
  • Mr. Jong Seong AhnOther Non-Executive Director
  • Mr. Jeong Hwa LeeOther Non-Executive Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Cellid Co Ltd's BVAC pipeline products use CeliVax technology for cancer therapeutic vaccines.
  • Seoul headquarters provides access to South Korean biotechnology research infrastructure.
  • 59 full-time employees focus on clinical research and development of immunotherapeutic vaccines.

Weaknesses

  • Limited employee count of 59 may restrict R&D capacity and market reach.
  • IPO in 2019 indicates a relatively young company with limited financial history.
  • Seoul location might limit access to global biotech talent pools outside Korea.

Opportunities

  • Expanding BVAC pipeline products could increase market share in cancer therapeutics.
  • South Korea's growing biotechnology sector offers potential for partnerships.
  • CeliVax technology may attract international research collaborations in Health Care.

Threats

  • Competition from established biotech firms in the Health Care sector.
  • Regulatory challenges in clinical trials for cancer therapeutic vaccines.
  • Dependence on BVAC pipeline products could pose business risk if development fails.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.